Provided by Tiger Trade Technology Pte. Ltd.

Invivyd, Inc.

0.9965
+0.04574.81%
Post-market: 0.9588-0.0377-3.78%19:57 EDT
Volume:5.43M
Turnover:5.19M
Market Cap:293.97M
PE:-2.74
High:1.03
Open:0.9450
Low:0.8664
Close:0.9508
52wk High:3.07
52wk Low:0.5031
Shares:295.00M
Float Shares:208.00M
Volume Ratio:0.99
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3641
EPS(LYR):-0.3048
ROE:-95.89%
ROA:-45.67%
PB:1.62
PE(LYR):-3.27

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), Century Therapeutics (IPSC)

TIPRANKS
·
May 19

Invivyd Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
May 18

Invivyd (IVVD) Q1 Loss Of US$41.4 Million Reinforces Bearish Unprofitability Narrative

Simply Wall St.
·
May 16

Why Invivyd (IVVD) Is Down 18.9% After Wider Q1 Loss And New Antibody Tolerability Data

Simply Wall St.
·
May 15

Invivyd post earnings selloff overdone, says H.C. Wainwright

TIPRANKS
·
May 15

Invivyd Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Invivyd Q1 FY26 net loss widens to $41.4 million; revenue rises to $13.74 million

Reuters
·
May 14

Invivyd Q1 net loss per share misses on higher R&D costs

Reuters
·
May 14

Invivyd Q1 EPS $(0.13) Misses $(0.07) Estimate, Sales $13.744M Miss $18.050M Estimate

Benzinga Earnings
·
May 14

BRIEF-Invivyd Q1 EPS USD -0.13

Reuters
·
May 14

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
May 14

Invivyd Q1 Revenue USD 13.744 Million

THOMSON REUTERS
·
May 14

Invivyd Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 12

Invivyd plans LIBERTY trial comparing VYD2311 tolerability with mRNA COVID vaccine

Reuters
·
May 11

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of Covid Monoclonal Antibody and Comparing Results to Covid Vaccination

THOMSON REUTERS
·
May 11

Invivyd to host first-quarter results, corporate update call

Reuters
·
May 07

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 05

Invivyd chairman Marc Elia speaks at POLITICO Health Care Summit

Reuters
·
Apr 20

Invivyd Announces Chairman Marc Elia to Speak at Politico Health Care Summit

THOMSON REUTERS
·
Apr 20

Invivyd Says Study of Potential COVID-19 Treatment Shows 'High End' Efficacy; Measles Candidate Introduced

MT Newswires Live
·
Apr 09